Ambrilia Biopharma Inc.
TSX : AMB

Ambrilia Biopharma Inc.

September 10, 2008 16:00 ET

Ambrilia to Present at the Sachs 8th Annual Biotech in Europe Investor Forum

MONTREAL, QUEBEC--(Marketwire - Sept. 10, 2008) - ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS

Ambrilia Biopharma Inc. (TSX:AMB) today announced that Dr. Philippe Calais, President and CEO, will present the Company and its projects at the Sachs Associates 8th Annual Biotech in Europe Investor Forum to be held in Zurich, September 23-24. This presentation will take place on Tuesday, September 23, Basel room (Swissotel), at 2:30 pm local time.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site: www.ambrilia.com

Contact Information